PSA-måling og prostatakreft - overdiagnostisering og overbehandling?

Tidsskrift for den Norske Laegeforening

Volumn 133, Issue 16, 2013, Pages 1711-1716

  Breidablik, Hans Johan ^a   Meland, Eivind ^b   Aakre, Kristin Moberg ^c   Førde, Olav Helge ^d,e  

^a Helse Førde HF ^*  (Norway)

^b Institutt for global helse og samfunnsmedisin   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e Helse Nord IKT   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BLOOD; CLINICAL PRACTICE; EARLY DIAGNOSIS; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; QUESTIONNAIRE; REGISTER; UNNECESSARY PROCEDURE; ARTICLE; PROSTATE TUMOR; STANDARD; UTILIZATION REVIEW;

ADULT; AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REGISTRIES; UNNECESSARY PROCEDURES;

EID: 84887384974     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.13.0023     Document Type: Article

References (28)

1. Mooi WJ, Peeper DS. Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006; 355: 1037-46.
2. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-9.
3. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Oslo: Helsedirektoratet, 2009.
4. Cancer in Norway 2010-Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Kreftregisteret, 2012.
5. Welch HG. Overdiagnosed. Boston, MA: Beacon Press, 2011.
6. Montie JE, Wood DP Jr, Pontes JE et al. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989; 63: 381-5.
7. Sakr WA, Grignon DJ, Haas GP et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138-44.
8. Albin RJ. «The Great Prostata Mistake». New York Times 9.3.2010.
9. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2012.
10. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
11. Sandblom G, Varenhorst E, Rosell J et al. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011; 342: d1539.
12. Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med 2009; 360: 1310-9.
13. Doherty R, Almallah Z. Urinary incontinence after treatment for prostate cancer. BMJ 2011; 343: d6298.
14. Norderhaug IN, Wisløff T, Fosså S et al. Formidling av kunnskapsbasert informasjon om PSA-test og prostatakreft til leger. Tidsskr Nor Lægeforen 2004; 124: 2893-5.
15. Kvåle R, Auvinen A, Adami HO et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007; 99: 1881-7.
16. Aakre KM, Thue G, Subramaniam-Haavik S et al. Diagnosing microalbuminuria and consequences for the drug treatment of patients with type 2 diabetes: a European survey in primary care. Diabetes Res Clin Pract 2010; 89: 103-9.
17. Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost 2009; 35: 695-710.
18. Lenzer J. Experts consider how to tackle overtreatment in US healthcare. BMJ 2012; 344: e3144.
19. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61.
20. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-13.
21. Parker C. Treating prostate cancer. BMJ 2012; 345: e5122.
22. Bill-Axelson A, Holmberg L, Filén F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54.
23. Nordström T, Aly M, Clements MS et al. Prostatespecific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013; 63: 419-25.
24. Fosså SD, Egey A, Haukaas SA et al. Feilaktig om hormonbehandling ved prostatakreft. Tidsskr Nor Legeforen 2009; 129: 429.
25. Carlsen B, Norheim OF. «Saying no is no easy matter» a qualitative study of competing concerns in rationing decisions in general practice. BMC Health Serv Res 2005; 5: 70.
26. Elwyn G, Frosch D, Thomson R et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012; 27: 1361-7.
27. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ 2013; 346: f325.
28. Määttänen L, Auvinen A, Stenman UH et al. Threeyear results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 2001; 93: 552-3.